Effects of Sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Raut, Chandrajit P ^a,c   Boucher, Yves ^b,c   Duda, Dan G ^b,c   Morgan, Jeffrey A ^a,c   Quek, Richard ^a,c,d   Ancukiewicz, Marek ^b,c   Lahdenranta, Johanna ^b,c   Eder, J Paul ^a,c,e   Demetri, George D ^a,c   Jain, Rakesh K ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; ERYTHEMA MULTIFORME; ERYTHROCYTE COUNT; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LEG PAIN; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; MYALGIA; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; PRURITUS; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTE; TISSUE PRESSURE; TUMOR BIOPSY; TUMOR VOLUME; BLOOD; CAPILLARY PERMEABILITY; CLINICAL TRIAL; DRUG EFFECT; EXTRACELLULAR FLUID; MIDDLE AGED; PRESSURE; SALVAGE THERAPY; SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CAPILLARY PERMEABILITY; EXTRACELLULAR FLUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PRESSURE; PROTEIN KINASE INHIBITORS; PYRIDINES; SALVAGE THERAPY; SARCOMA; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84856743032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026331     Document Type: Article

References (41)

1. Peng CL, Guo W, Ji T, Ren T, Yang Y, et al. (2009) Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 8: 1729-1736.
2. Flaherty KT, (2007) Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7: 617-626.
3. Adnane L, Trail PA, Taylor I, Wilhelm SM, (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
5. Gutmann R, Leunig A, Leunig M, Feyh J, (1993) [Importance of increased interstitial fluid pressure in therapy of malignant tumors of the head-neck area]. Laryngorhinootologie 72: 338-341.
6. Tufto I, Rofstad EK, (1998) Interstitial fluid pressure, fraction of necrotic tumor tissue, and tumor cell density in human melanoma xenografts. Acta Oncol 37: 291-297.
7. Tufto I, Rofstad EK, (1999) Interstitial fluid pressure and capillary diameter distribution in human melanoma xenografts. Microvasc Res 58: 205-214.
8. Yeo SG, Kim JS, Cho MJ, Kim KH, (2009) Interstitial fluid pressure as a prognostic factor in cervical cancer following radiation therapy. Clin Cancer Res 15: 6201-6207.
9. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK, (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694.
10. Boucher Y, Leunig M, Jain RK, (1996) Tumor angiogenesis and interstitial hypertension. Cancer Res 56: 4264-4266.
11. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, et al. (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52: 6371-6374.
12. Nathan SS, DiResta GR, Casas-Ganem JE, Hoang BH, Sowers R, et al. (2005) Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11: 2389-2397.
13. Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, et al. (2009) Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Ann Acad Med Singapore 38: 1041-1047.
14. Stohrer M, Boucher Y, Stangassinger M, Jain RK, (2000) Oncotic pressure in solid tumors is elevated. Cancer Res 60: 4251-4255.
15. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, et al. (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695-6698.
16. Boucher Y, Salehi H, Witwer B, Harsh GRt, Jain RK, (1997) Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 75: 829-836.
17. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, et al. (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61: 6400-6405.
18. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
19. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
20. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
21. Ogawa Y, Kawamura T, Furuhashi M, Tsukamoto K, Shimada S, (2008) Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci 51: 190-199.
22. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, et al. (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934.
23. Heldin CH, Rubin K, Pietras K, Ostman A, (2004) High interstitial fluid pressure- an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
24. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338.
25. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
26. Duda DG, Cohen KS, Scadden DT, Jain RK, (2007) A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2: 805-810.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
28. Hollander M, Wolfe DA, (1973) Nonparametrical Statistical Inference New York John Wiley & Sons.
29. Brown MB, Benedetti JK, (1977) Sampling behavior of test for correlation in two-way contingency tables. J Am Statistical Assoc 72: 309-315.
30. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, et al. (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27: 3133-3140.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
32. Zhu AX, Raymond E, (2009) Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther 9: 143-150.
33. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, et al. (2011) Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res 17: 918-927.
34. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM, (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 16: 4853-4863.
35. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27: 3020-3026.
36. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, et al. (2011) Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Mullerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig 4: 26-33.
37. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, et al. (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823.
38. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, et al. (2011) Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 103: 325-332.
39. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17: 2074-2080.
40. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574.
41. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.